key: cord-0768929-u9st5mg6
authors: Jajodia, Surabhi; Goenka, Usha; Jas, Debraj; Tiwary, Indrajeet; Goenka, Mahesh Kumar
title: ENDOVASCULAR MANAGEMENT OF MASSIVE HAEMOPTYSIS DUE TO COVID-19 RELATED PULMONARY ARTERY PSEUDOANEURYSM: A RARE ENTITY
date: 2021-08-27
journal: Radiol Case Rep
DOI: 10.1016/j.radcr.2021.08.048
sha: 798066d8ffdf32604bc71f78ddc1ad57976346ff
doc_id: 768929
cord_uid: u9st5mg6

Pulmonary artery pseudoaneurysms are rare causes of massive haemoptysis, even less common in setting of COVID-19 pneumonia. We describe and discuss an index case of cavitating COVID-19 pneumonia complicated by a pulmonary artery pseudoaneurysm without concomitant pulmonary thromboembolism. The patient presented with severe haemoptysis and was managed by endovascular coil embolization. Good technical and clinical success was achieved with complete resolution of haemoptysis.

Over the past one and a half years, since the global outbreak of the COVID-19 pandemic in January 2020, the world has witnessed several novel and atypical manifestations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus). These encompass numerous pulmonary as well as extra-pulmonary clinical ramifications, posing unprecedented challenges to patients as well as physicians. (1) Haemoptysis is a rarely described symptom in COVID-19 pneumonia, with reported prevalence of 2-3%. (2, 3) Most of the reported cases of haemoptysis occurred early in the course of the disease and were most often non-massive. Massive haemoptysis refers to an expectorated blood volume of 100 to 1000 ml within 24 hours causing significant threat to life, if untreated. (4, 5) Very few cases of massive haemoptysis associated with COVID-19 infection have been described in literature, most of which occurred secondary to thromboembolic disease, anticoagulant therapy, vasculitis, or secondary fungal infection. (6) (7) (8) Pulmonary arterial pseudoaneurysms (PAP) are rare and potentially fatal causes of haemoptysis and can be acquired or idiopathic. Trauma, vasculitis, infections like fungal (mycotic aneurysms) and tuberculosis (Rasmussen aneurysm), neoplasia, pulmonary hypertension and Hughes-Stovin Syndrome have been described as aetiological factors in development of pulmonary arterial aneurysm (PAA) / pseudoaneurysms. (8, 9) At the time of writing this article, on thorough PubMed (PubMed.gov) search, we could find only three previously published case reports of PAAs / PAPs related with vasculitic and thromboembolic pathophysiology of COVID-19 infection. (8, 10, 11) We present interesting sequelae of COVID-19 pneumonia with fibro-cavitary disease. The patient presented with massive haemoptysis secondary to a pulmonary arterial pseudoaneurysm, in absence of pulmonary thromboembolism. We managed the case successfully with endovascular embolization. This article aims to emphasize on yet another uncommon facet of the COVID-19 spectrum, where early detection and prompt treatment are of paramount importance, to circumvent a potential casualty.

Case Report:

History: A 61-year-old gentleman presented to the emergency department after an episode of acute massive life-threatening haemoptysis (approximately 120 ml) with significant respiratory distress. He gave a 3-month history of persistent cough with expectoration since he tested positive for COVID-19 pneumonia. He also had a few interspersed episodes of streaky haemoptysis since a week prior to presentation, that had resolved spontaneously. During his prior long admission for severe COVID-19 pneumonia (CT Involvement Score of 18/25) at another hospital, he had received intravenous methylprednisolone, remdesivir, tocilizumab, prophylactic subcutaneous enoxaparin and high flow nasal oxygen. His CRP and D-dimer levels were mildly elevated (CRP -3 mg/L; D-dimer -2.03 µg/mL). He was also a known diabetic on medication. A recent high resolution computed tomography (HRCT) of chest showed bilateral fibrotic sequelae of COVID pneumonia and cavitary areas of breakdown in right lung (Figure 1 ). The patient tested negative for COVID-19 pneumonia on nasopharyngeal polymerase chain reaction (PCR) swab at admission and was shifted to Respiratory intensive treatment unit (RITU) in view of the severity of haemoptysis and low oxygen saturation (83%). Patient was administered 1 gram of Tranexamic acid, put on Bilevel Positive Airway Pressure (BiPAP), and transfused with 2 units of packed red blood cells, prior to shifting to the CT suite for a CT Pulmonary Angiogram (CTPA).

Imaging: CTPA revealed a large right lower lobar PAP within a cavitating area in right lower lobe consolidation. In addition, multiple ground glass alveolar infiltrates were scattered in both lungs, suggesting alveolar haemorrhage. Background fibro-reticular changes were seen in both lungs causing architectural distortion, in keeping with fibrotic sequelae of COVID-19 pneumonia ( Figure 2 ). Bronchial arteries were not hypertrophic or prominent.

Treatment: The patient was planned for an emergency endovascular embolization procedure of the pulmonary pseudoaneurysm in the Interventional Radiology Cath-lab suite. Right common femoral vein access was secured under ultrasound guidance, using a 6 French (F) 11 cm (Cordis®) sheath. The right main pulmonary artery was initially cannulated with a 4 French 100 cm multi-purpose A-2 (MPA2) catheter (Cordis®) and a contrast pulmonary angiogram was performed. After this the short sheath was replaced by 6 French 55 cm Flexor sheath (Cook Medical®), with tip placed in the distal pulmonary trunk. The right lower lobe pulmonary artery was selectively cannulated with a 5 French 80 cm Cobra (C1) catheter (Cook Medical®). Selective contrast angiograms done from branches of the left lower lobe artery demonstrated and confirmed a bi-lobulated large 14 mm PAP arising from the right postero-basal pulmonary arterial branch. There was on-table massive haemoptysis on cannulation of branch supplying pseudoaneurysm, which was clearly demonstrated on angiogram, showing contrast spill into the right lower lobe bronchus and then into the main tracheo-bronchial tree. The pseudoaneurysm was quickly embolised using multiple 0.035"coils of 4 to 7 mm diameter (MReye® Embolization Coil, Cook Medical). Total of 7 coils were deployed to achieve total embolization of both lobules of the aneurysm with complete stasis of culprit branch. An optimal post-procedure angiographic result was obtained (Figure 3 ).

Outcome and follow-up: There were no further episodes of haemoptysis in the two-week follow up period. Oxygen saturation also improved subsequent to the procedure. Superimposed fungal infection and co-infection with mycobacterium tuberculosis (MTB) or other organisms were ruled out by negative Acid-Fast stain and culture of bronchoalveolar lavage specimen. An interval contrast enhanced follow-up CT confirmed successful embolization of the pseudoaneurysm (Figure 4 ).

Massive haemoptysis is potentially life threatening, and most often has origin in bronchial arterial circulation, accounting for approximately 90% of cases. Non-bronchial systemic arterial or venous source has been described in 5% cases, while pulmonary arteries are contributary only in 5% of patients with haemoptysis. (5) Pulmonary arterial pseudoaneurysms (PAPs) are extremely rare entities and have a predilection for peripheral pulmonary arteries. Although uncommon, there is ample published literature on acquired PAPs, secondary to tuberculosis, fungal (Aspergillosis, Mucormycosis) and syphilis, lung abscesses, septic emboli (mycotic aneurysms), vasculitis, trauma, neoplasia, etc. (8, 9) Rasmussen aneurysms are PAPs described in relation with chronic cavitary tuberculosis and occur due to direct local endothelial injury and weakening of arterial wall, with high risk of rupture. (5, 8) Massive haemoptysis is very infrequently seen with COVID-19 infection and is usually secondary to pulmonary thromboembolism and anticoagulation. (6-8) On extensive literature search, we came across only two case reports wherein PAPs secondary to COVID-19 pneumonia caused massive haemoptysis. Both these patients had an associated underlying pulmonary arterial thromboembolism, secondary to inflammatory and vasculitic pathophysiology of COVID-19 virus and resultant immuno-thrombogenesis and endothelial dysfunction. (8,11) Baeza I et al (7) published a case of COVID-19 associated pulmonary aspergillosis (CAPA), who presented with massive haemoptysis due to pseudoaneurysm of right intercosto-bronchial trunk. Densos C et al (10) described three patients with severe COVID-infection on veno-venous extracorporeal membrane oxygenation (VV-ECMO). All these patients developed a multi-system inflammatory syndrome and presented with polyarteritis nodosa (PAN)-like vasculitis. Contrast enhanced CT revealed multifocal aneurysmal dilation of pulmonary as well as other systemic arteries. The authors concluded that a combination of "cytokine storm" associated with a pro-coagulant state, and ECMO induced coagulopathy and haemostasis resulted in such vasculopathy in these patients.

CTPA is the investigation of choice for haemoptysis to look for underlying vascular or pulmonary causes. PAPs appear as focal outpouchings in relation to pulmonary arterial branch well demonstrated in the pulmonary arterial phase after contrast injection. (9) Prior to planning any endovascular intervention, CTPA is essential for understanding the anatomy and localization of the pseudoaneurysm. CTPA also helps to map the bronchial arteries and assess their calibre to ascertain the need for an additional bronchial artery embolization. Pulmonary angiography and embolization have been established as the management of choice in managing haemoptysis resulting from PAPs, with good technical and clinical success. Coils, gel foam, vascular plugs, glue, or endovascular stents can be used for exclusion or occlusion of the pseudoaneurysm. (8, 9) We used multiple 0.035" coils, to ensure cost compliance and safe, permanent and selective embolization.

The pathogenesis SARS-CoV-2 virus has been hypothesised to have two basic componentsproinflammatory and immuno-thrombogenic. Infiltration of lungs and pulmonary vasculature with inflammatory cells lead to a cascade of inflammatory responses with complement activation, leucocyte and platelet recruitment, cytokine storm, and resultant endothelial dysfunction. Such endothelial damage has been directly linked with vasculitis, resembling that in PAN / Kawasaki disease. (11) Adaptive immune response and thrombin activation culminate in micro-thrombotic complications like pulmonary and deep vein thrombosis and stroke. Moreover, although uncommon, pulmonary cavitation has been documented in severe cases of COVID-19 pneumonia requiring intensive care. Zoumot Z et al (12) postulated a multifactorial cause of cavitation, including bacterial and fungal co-infection, the immunosuppressive effects of glucocorticoids and Tocilizumab, SARS-CoV-2 specific inflammatory pathways and increased propensity for pulmonary micro-infarcts and subsequent cavitation. Our patient also had a pulmonary cavity associated with the pseudoaneurysm in the right lower lobe, with no microbiological, serological, or clinical evidence of fungal, tubercular, or bacterial infection. We speculate that besides the severe inflammation and endothelial dysfunction related to COVID-19 infection resulting in weakening of the arterial wall, the cavitary pneumonia may be associated with the development of the PAP, much like formation of Rasmussen's aneurysms in chronic cavitary tuberculosis.

We describe, an index case of PAP presenting as a late complication of cavitating COVID-19 pneumonia, without any concomitant pulmonary thromboembolism. PAPs are rare entities and can be missed on HRCT of chest, routinely done in setting of COVID-19 infection. With most institutions adopting a protocol of administering prophylactic anticoagulation in patients with elevated D-dimer levels due to severe COVID-19 infection, those with incidental PAPs can present with fatal haemoptysis. PAPs need to be recognized early and treated urgently to reduce risk of mortality. Therefore, we wish to highlight the role of CTPA in the diagnostic armamentarium for patients with severe COVID-19 pneumonia. We also recommend a more selective and judicious anticoagulation in these patients, particularly those presenting with fibro-cavitating pneumonia.

While a sea of information is consistently emerging regarding the myriad aspects of the COVID-19 clinical spectrum, we describe a novel entity of cavitating COVID related PAP causing massive haemoptysis, which we managed successfully using endovascular coil-embolization. It is important for clinicians and radiologists to promptly recognize the possibility of PAP in setting od COVID-19, especially fibro-cavitating type, to ensure prompt and holistic management. 

The many faces of coronavirus disease 2019: COVID-19 and the liver

Haemoptysis as the first presentation of COVID-19: a case report

Case Series of COVID-19 Presenting with Massive Hemoptysis

Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review

Diagnosis and management of hemoptysis

COVID-19 pneumonia with hemoptysis: Acute segmental pulmonary emboli associated with novel coronavirus infection

Massive hemoptysis due to Aspergillus-related pulmonary artery pseudoaneurysm in a patient with COVID-19 pneumonia

Pulmonary artery pseudoaneurysm secondary to COVID-19 treated with endovascular embolisation

Pulmonary Artery Pseudoaneurysm: A Rare Cause of Fatal Massive Hemoptysis. Case Rep Pulmonol

Spontaneous hemothorax in 4 COVID-19 ARDS patients on VV-ECMO revealing pulmonary artery aneurysms. Crit Care

CT chest with pulmonary angiography as a diagnostic tool in clinically suspected RT-PCR-negative COVID-19 pneumonia with pulmonary artery aneurysm

Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease